• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Valeo Pharma Appoints President, COO

    Metrion, LifeArc Extend Neuroscience Alliance

    Grifols Begins COVID-19 Plasma Treatment Trial

    Janssen, TenNor Enter NTM Research Pact

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Metrion, LifeArc Extend Neuroscience Alliance

    Grifols Begins COVID-19 Plasma Treatment Trial

    Janssen, TenNor Enter NTM Research Pact

    Virtual Clinical Trials: The Future of Dermatology Studies

    Cognate BioServices Announces Major Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Alcami

    Flow Sciences

    Cytovance Biologics

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Adare Pharma Solutions

    Emergent BioSolutions

    Flow Sciences

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    A Potential “Marriage”

    Initiator companies and generics/CMOs working together.

    A Potential “Marriage”
    Related CONTENT
    • Virtual Clinical Trials: The Future of Dermatology Studies
    • Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    • RheinCell Therapeutics Achieves GMP Certification
    • Almac Sciences Secures Support from Invest NI
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    Emil W. Ciurczak, DoraMaxx Consulting11.17.20
    For centuries, armies obtained needed supplies from newly conquered areas as they advanced. Since they carried their swords, shields, etc. with them, all they needed was food and firewood to survive and continue forward. As we “progressed,” our needs became more complex and a supply-chain needed to be maintained for success. Some prime examples are the British army in Continental U.S., Napoleon in Russia, and, my favorite, Rommel in N. Africa. These powerful forces were stalled by lack of resources, not necessarily an overpowering opponent. So, substitute the COVID pandemic for the Russians burning Moscow and you see some parallels. [My $40 Timex, getting five years on a battery, demonstrates that, sometimes, simpler is better.]

    Last month, I ended with a thought or two about cooperative projects between initiator companies and (usually) smaller generic or contract manufacturing firms with, of course, the proviso that such “marriages” do not violate anti-trust laws. Before you say this cooperative is impossible, let me give you an example—albeit much smaller—of such an effort.

    Back in the late1980s, early 1990s, companies were beginning to take an interest in measuring processes in real time. The control methods, at that time, for example, consisted of such methods as using a “sample thief” to extract a number of samples from a blending bin, send them to QC and, based on the results, declare the blend mixed, or not. I had published a paper using a fiber optic probe, pushed into the bed to determine uniformity by Near-Infrared Spectroscopy. Pfizer went quite a bit farther.

    Understanding that any one of their blockbuster drugs (Lipitor, for example) had sales in excess of the combined sales of all instrument companies, worldwide, they realized they could not ask a much smaller instrument company to invest a significant portion of its time and fortune in developing a specialized instrument that a Pfizer might or might not buy, after all. So, they came up with a plan that has become a “new normal” in PAT/QbD circles.

    The first (“PAT-type”) in-process instrument was a joint project between Pfizer (Sandwich, UK) and Zeiss optics (Zurich, CH). A lab-style near-infrared spectrometer was mounted on a v-blender with a window in one end cap. Since no R&D was done prior to the experiment, there were still wires coming from the instrument: one from a power source and another to the computer. The blender was rotated a single one-half spin in one direction, the one-half spin in the other direction to avoid breaking or binding the wires. When it appeared to be giving meaningful results, Zeiss developed the unit with an internal power source and wireless capacity. The device/technique was patented, but not “defended,” allowing all companies to use the procedure in their processes. This process monitoring device changed the entire paradigm of the powder blending step in a manufacturing process.

    This big/small company cooperative model can work in many ways:
    1. An initiator company would develop the dosage form/process as usual and, as the successful product increases in sales, it can clone its process equipment and distribute them to subsidiary companies (either co-ops or wholly-owned), quickly validate them, and proceed to produce the drug at multiple sites.
    2. The initiator company can develop the process and sub-let it to a contract manufacturing company. This would be an exclusive license and all the products produced are sold under the initiator’s name. When the patent expires, the contract would end and a new paradigm would need to be negotiated.
    3. Then, we have the concept of a sponsor-company subsidizing an entire PAT/QbD process(es) at a contract location, with the CRO/CMO developing everything from the clinical supplies, through the final dosage form, through actual production and distribution of the commercial supplies.

    The best part of this (these) situation(s) is that any or all of the contract locations would not be dependent on a single supply source for raw materials. Since the overall scope of QbD is to modify the process to affect the outcome, variances in raw materials are overcome through changing the settings/parameters of the Design Space—all previously validated, accepted changes to the process, which allows the intermediate and final product to meet specifications. The reason that we have specified excipients from specific vendors is that, under the cGMP (batch) manufacturing paradigm, processes (and amounts of materials, e.g., lubricants, such as magnesium stearate) cannot be legally varied even though some experienced operators make “corrections” to the batches to “assure” they meet specs.

    This does not mean that all standards for raw materials will be discarded, but that two things are (painfully) apparent:
    1. Current specifications are based on purity, not performance. Since almost all the specs (as in USP, EP, etc.) were formulated decades ago when pharmacists made small batches of pills or capsules in the back rooms of their pharmacies, easy tests, such as tap density, color, heavy metals, and sieve size were all that were needed, since there was no processing as we know it today. This assumed that the supplies were all locally obtained (or from a small number – or one – nationally based vendor(s)), so only id and purity needed to be tested. Manually blended small batches didn’t need physical parameters specified.
    2. Since modern pharmaceutical manufacturing is so dependent on the physical structure of the ingredients, the two choices are to sit down with vendors and agree upon delivery of tightly controlled materials or, the companies can adopt a true QbD program, which allows physical variation (of course, still maintaining chemical purity), which allows manufacturers to use local vendors, saving inter-state and inter-country shipping of materials.

    This ability to not be held captive by a supply chain is step one. Now, we can look at quality. Quality isn’t a vague concept; it is rather easily defined. Some of the hallmarks of a quality product (and its process) are:
    1. Obviously, a product that consistently meets product performance criteria in physical and chemical tests (assay, dissolution, etc.).
    2. Monitoring each step to avoid waste and shorten the time between steps (minimum PAT set-up). This leads to a faster through-put, making better use of manufacturing equipment.
    3. Quality, from a somewhat selfish point of view, means avoiding the hassle of recalls and or destroyed batches that do not meet standards.
    4. All these (1-3) points lead to a reduced COGS and assuring that their orders to distributers are met (especially since, if a generic product, there are many competitors waiting to step in).

    Now that we have the ingredient difference problem addressed, we can look at the manufacturing sites. The traditional (a.k.a., “old-fashioned”) production process has been:
    1. Do the preliminary formulation work. (Including clinical batches)
    2. Do a scale-up (batch process) on the chosen formulation and write the SOPs for the process.
    3. Begin producing the final product, using traditional multi-step processes, at the site of origin.
    4. If the product is successful, attempt to mirror the process at your other sites or, as we are seeing in recent years, contract the (GMP) process to CMOs around the world.

    At this point of a successful product, the traditional approaches as the patent life expires were:
    1. Drop prices during the patent’s last year, hoping to sell a percentage of the product, based on name recognition and reputation.
    2. Change the product design at the last minute, hoping to delay generic competition.
    3. Invent (excuse me), “discover” new uses for the older product to extend its patent life—think a lower dose Proscar (non-cancerous prostate tumors) being marketed as Propecia (male pattern baldness).

    Now, in the time of continuous manufacturing, built on sound scientific principles (QbD, Design of Experiments, real-time process monitoring instruments), it is possible and economically sound to reproduce the same manufacturing conditions in multiple locations: including contract manufacturing sites.

    This is where creative business decisions are needed. Getting back to the three scenarios, where CM units may be “cloned” and placed in subsidiaries to help keep up with demand, or placed on CMOs to either use them as contract producers with short-term contracts, ending or re-negotiated upon patent expiry date.

    The truly imaginative companies will find ways to “partner” with contract manufacturers. These solutions will range from outright paying them to produce the product(s) on equipment owned by and installed by the proprietary company to loaning the CMO the equipment for the duration of the product’s patent life to working out a plan wherein the CMO takes a portion of its fees towards eventually owning the continuous manufacturing unit(s).

    Clearly, there are positive aspects and speed-bumps in each case. The one clear positive that exists in all cases is that the speed and cost-savings and consistency of CM-made product will bring the ever-sought-after “quality” to the product. The scenario wherein the CM unit is merely “lent” to the CMO is the lowest cost to the contract facility, allowing smaller producers to bid successfully for the contract.

    Where the CMO is allowed to purchase the hardware (and expertise and training), either on a lay-away plan or through some profit-sharing method, it sets them up for being able to easily accept more contracts for CM-produced drugs. Ultimately, these well-equipped facilities can be used as resources for DoE experiments (virtual scale-ups) and potentially, with assistance, actual formulation work. A great advantage to that scenario is that all the R&D would be performed with locally sourced raw materials, obviating the need to modify the work performed by a central R&D facility.

    Since I am merely a humble chemist, I cannot even suggest methods for the financial structure of these proposals, nor can I imagine how the distribution of finished products could be integrated into the existing structure. But, all in all, I am sure that the financial wise people in both companies can work out something that will both lower costs and improve quality.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Suggested For You
    The Future of Clinical Trials Series: Part I The Future of Clinical Trials Series: Part I
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    RheinCell Therapeutics Achieves GMP Certification RheinCell Therapeutics Achieves GMP Certification
    Almac Sciences Secures Support from Invest NI Almac Sciences Secures Support from Invest NI
    Baxter, Novavax Ink Sterile Manufacturing Agreement Baxter, Novavax Ink Sterile Manufacturing Agreement
    Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    Aurigene Pharmaceutical Services ltd. Aurigene Pharmaceutical Services ltd.
    Parexel Appoints Chief Patient Officer Parexel Appoints Chief Patient Officer
    Angelini Pharma Acquires Arvelle Therapeutics for $960M Angelini Pharma Acquires Arvelle Therapeutics for $960M
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Natoli Engineering Appoints Northeast Service Technician Natoli Engineering Appoints Northeast Service Technician
    BioNTech, Shanghai Fosun Pharma to Supply COVID-19 Vax to China BioNTech, Shanghai Fosun Pharma to Supply COVID-19 Vax to China
    Collaboration Creates Bio Hub in Northern UK Collaboration Creates Bio Hub in Northern UK
    Got Floor Space? – Increase Workspace Efficiency Got Floor Space? – Increase Workspace Efficiency

    Related Columns

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20

    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20


    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20


    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20

    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20


    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20

    • Supply Chain
      What We Have is Failure to Communicate

      What We Have is Failure to Communicate

      When it comes to implementing track and trace technology, why is Pharma dragging its feet?
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.20

    • Vision: 2020

      Vision: 2020

      You have exactly 366 days in 2020 to bring your clarity of vision to reality.
      Ben Locwin 01.28.20


    • Solid Dosage/Creams/Ointments
      The “Greening” of Solid Dosage Form Manufacturing

      The “Greening” of Solid Dosage Form Manufacturing

      Going “green” can mean saving big bucks for pharma manufacturers.
      Emil W. Ciurczak, DoraMaxx Consulting 11.20.19

    • When Life Gives You Lemons…Raise Your Drug Prices

      When Life Gives You Lemons…Raise Your Drug Prices

      The hidden effect of economic models on global drug supply and shortages.
      Ben Locwin 11.20.19

    • Like It’s 1999

      Like It’s 1999

      Reflecting on 20 years of Contract Pharma.
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 10.15.19

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Tonix And Fujifilm Enter COVID-19 Vax Deal
    • Virtual Clinical Trials: The Future Of Dermatology Studies
    • Sanofi Unveils EUROAPI As Name Of New European API Company
    Breaking News
    • Valeo Pharma Appoints President, COO
    • Metrion, LifeArc Extend Neuroscience Alliance
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Janssen, TenNor Enter NTM Research Pact
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Maternal Dietary Intake of Fish, Omega-3s, and Omega-6s Linked to Child Neurodevelopment
    Short Term Low-Carb Diet Linked to Remission of Type 2 Diabetes
    Brown Fat Associated with Reductions in Chronic Disease Risk
    Coatings World

    Latest Breaking News From Coatings World

    PPG Completes COLORFUL COMMUNITIES Project at School in A. Bangsaothong Samutprakarn, Thailand
    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    OQ Chemicals Announces Carboxylic Acids Price Increase
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FineHeart Successfully Tests Wireless TET System
    Apria Healthcare Settles Whistleblower Lawsuit
    OraSure’s OMNIgene·ORAL Device Included in COVID-19 EUA Amendment
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Valeo Pharma Appoints President, COO
    Metrion, LifeArc Extend Neuroscience Alliance
    Grifols Begins COVID-19 Plasma Treatment Trial
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    JLo Beauty Launches at Sephora & Amazon
    Unilever and Alibaba Group Join Forces
    Redken Unveils Acidic Bonding Concentrate Range
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    Manscaped Expands Further in Europe
    Color Street Gives Back
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Ontex Honored for Mask Production
    TFP Acquires PV3 Technologies
    Shemesh Adds U.S. Headquarters
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    OrthoPediatrics Expands Agent Network in Three European Countries
    Studies Show FlareHawk Expandable Cage Delivers Favorable Fusion, Patient Outcomes
    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login